Overview and Scope
Regenerative medicine for cartilage refers to a medication used during surgery to repair damaged cartilage in the knees using body-produced cells that can create cartilage. A biopsy is required to collect chondrocytes (cells that produce cartilage), which are then multiplied in a lab before being implanted into the injured area during surgery.
Sizing and Forecast
The regenerative medicine for cartilage market size has grown strongly in recent years. It will grow from $4.24 billion in 2023 to $4.48 billion in 2024 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to regenerative medicine market resulted from rising prevalence of chronic diseases, emerging markets growth, implementation of the 21st century cures act, rapid growth in aging population, and the improvement in healthcare awareness and expenditure.
The regenerative medicine for cartilage market size is expected to see strong growth in the next few years. It will grow to $5.64 billion in 2028 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to rising demand for organ transplantations, growth in healthcare expenditure, technological advancements in regenerative medicines, rising investments in regenerative medicine research, and changes in lifestyles.. Major trends in the forecast period include growing use of mesenchymal stem cell technology, increasing research and development on use of novel gene therapy techniques, advancements in technology transfer and clinical translation, rising strategic collaborations, partnerships and agreements, growth and advent of new companies, injectable hydrogel role in cartilage repair as a regenerative medicine, and global research initiatives and funding.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/regenerative-medicine-for-cartilage-global-market-report
Segmentation & Regional Insights
The regenerative medicine for cartilage market covered in this report is segmented –
1) By Product: Cell Based, Gene Based, Tissue Based
2) By End-Use: Ambulatory Surgical Centers, Hospitals And Clinics, Others
3) By Application: Musculoskeletal, Oncology, Dental, Wound Care, Others
Europe was the largest region in regenerative medicine for cartilage in 2023. The regions covered in the regenerative medicine for cartilage market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3961&type=smp
Major Driver Impacting Market Growth
The growing incidence of osteoarthritis across the globe will drive the market for regenerative medicine for cartilage. Osteoarthritis is a degenerative joint disorder that mostly attacks the articular cartilage. According to the Arthritis Foundation, degenerative joint disease disorders such as osteoarthritis will impact at least 130 million individuals around the globe by 2050. Some of the most commonly used treatments for osteoarthritis are autologous chondrocyte implantation and scaffold implants. Thus, the increasing incidence of osteoarthritis is expected to drive the demand for the market for regenerative medicine for cartilage.
Key Industry Players
Major companies operating in the regenerative medicine for cartilage market report are Smith & Nephew plc, Integra LifeSciences, Stryker Corporation, MiMedx Group, Inc., Zimmer Biomet Holdings Inc., B. Braun Melsungen AG, AbbVie, CONMED Corporation, Arthrex Inc., Baxter International Inc.,, China Regenerative Medicine International, AstraZenaca, ABLbio, Adimmune, Henlius, Innovent Biologics, Bio-Thera, Hisun Pharma, 3SBio, Biocon, Dr.Reddy’s, Mylan, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, Cellgenix Gmbh, BioTissue Technologies, Corin Group, Medical Import Ltd., Lucideon, Orthonika, Merete, 3di GmbH, Aditus Medical GmbH, Anton Hipp GmbH, AREX SAS, Acelity L.P. Inc., Celgene Corporation, StemCells, Inc, Organogenesis Inc, NuVasive, Inc, Japan Tissue Engineering Co., Ltd, Advantagene, Inc., Mesoblast Ltd, Globus Medical, DePuy Synthes, Cryolife Inc, Johnson & Johnson, Medtronic Plc, Rti Surgical, CartiHeal, Inc., DJO Global Inc., Wright Medical Group, Auxein, Aesculap, Inc, AMEGA Biotech, BioMarin Pharmaceutical, Ache Laboratorios Farmaceuticos, Myralis Industria Farmaceuticaa, Biosonda Biotechnology, Ipsum Clinical, Steris Applied Sterilization Technologies
The regenerative medicine for cartilage market report table of contents includes:
1. Executive Summary
2. Regenerative Medicine For Cartilage Market Characteristics
3. Regenerative Medicine For Cartilage Market Trends And Strategies
4. Regenerative Medicine For Cartilage Market – Macro Economic Scenario
5. Global Regenerative Medicine For Cartilage Market Size and Growth
…
32. Global Regenerative Medicine For Cartilage Market Competitive Benchmarking
33. Global Regenerative Medicine For Cartilage Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Regenerative Medicine For Cartilage Market
35. Regenerative Medicine For Cartilage Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
